Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study
- PMID: 31271705
- DOI: 10.1111/jth.14561
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study
Abstract
Background: Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is suggested in this patient population, but evidence supporting this approach is limited.
Methods: The Hokusai VTE Cancer trial compared edoxaban with dalteparin for VTE treatment in patients with active cancer. This post hoc analysis focused on the follow-up period from 6 to 12 months. The primary outcome was the composite of adjudicated first recurrent VTE or major bleeding. Secondary outcomes included recurrent VTE, major bleeding, and clinically relevant bleeding.
Results: Of the 522 and 524 patients randomized to edoxaban or dalteparin, 294 (56%) received edoxaban and 273 (52%) received dalteparin for more than 6 months (median duration of 318 and 211 days, respectively). Between 6 and 12 months, the primary outcome during study treatment occurred in seven patients (2.4%) in the edoxaban group and six patients (2.2%) in the dalteparin group (unadjusted hazard ratio 1.05; 95% confidence interval, 0.36-3.05). Recurrent VTE occurred in two patients (0.7%) in the edoxaban group and in three patients (1.1%) in the dalteparin group, whereas major bleeding occurred in 5 (1.7%) and three patients (1.1%), respectively.
Conclusions: The rates of recurrent VTE or major bleeding are relatively low among patients with active cancer receiving extended anticoagulant therapy beyond 6 months. Extended treatment with oral edoxaban appears as effective and safe as subcutaneous dalteparin.
Keywords: cancer; edoxaban; hemorrhage; low-molecular-weight heparin; venous thromboembolism.
© 2019 International Society on Thrombosis and Haemostasis.
Similar articles
-
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.Thromb Haemost. 2018 Aug;118(8):1439-1449. doi: 10.1055/s-0038-1667001. Epub 2018 Jul 30. Thromb Haemost. 2018. PMID: 30060256 Clinical Trial.
-
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.Thromb Haemost. 2015 Nov 25;114(6):1268-76. doi: 10.1160/TH15-06-0452. Epub 2015 Aug 13. Thromb Haemost. 2015. PMID: 26271200 Clinical Trial.
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.Thromb Haemost. 2010 Sep;104(3):642-9. doi: 10.1160/TH10-02-0142. Epub 2010 Jun 29. Thromb Haemost. 2010. PMID: 20589317 Clinical Trial.
-
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.J Cardiovasc Pharmacol Ther. 2017 May;22(3):230-238. doi: 10.1177/1074248416675732. Epub 2016 Nov 2. J Cardiovasc Pharmacol Ther. 2017. PMID: 27811198 Review.
-
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.Drugs. 2015 Nov;75(17):2025-34. doi: 10.1007/s40265-015-0495-6. Drugs. 2015. PMID: 26546477 Review.
Cited by
-
Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients.Ann Hematol. 2023 Sep;102(9):2599-2605. doi: 10.1007/s00277-023-05369-1. Epub 2023 Jul 21. Ann Hematol. 2023. PMID: 37479891
-
Acute reperfusion treatment and secondary prevention of cancer-related stroke: comprehensive overview and proposal of clinical algorithm.Ther Adv Neurol Disord. 2023 Jun 16;16:17562864231180717. doi: 10.1177/17562864231180717. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37342814 Free PMC article. Review.
-
Comparison of long-term complications in cancer patients with incidental and acute symptomatic venous thromboembolism.Front Cardiovasc Med. 2023 May 19;10:1118385. doi: 10.3389/fcvm.2023.1118385. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37273873 Free PMC article.
-
Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study.J Cancer Sci Clin Ther. 2021 Aug 11;5(3):347-362. doi: 10.26502/jcsct.5079122. J Cancer Sci Clin Ther. 2021. PMID: 37169025 Free PMC article.
-
Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy.Res Pract Thromb Haemost. 2023 Mar 10;7(2):100115. doi: 10.1016/j.rpth.2023.100115. eCollection 2023 Feb. Res Pract Thromb Haemost. 2023. PMID: 37063761 Free PMC article.
References
REFERENCES
-
- Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001275.
-
- Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;111:2339-46.
-
- Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-8.
-
- Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-50.
-
- Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654-6.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical